Home>
US Stocks>
Supernus Pharmaceuticals

Supernus Pharmaceuticals share price today

(SUPN)

Supernus Pharmaceuticals share price is $35.6 & ₹3,033.05 as on 25 Dec 2024, 2.30 'hrs' IST

$35.6

▲

0.01

(0.03%)

Market is closed - opens 8 PM, 26 Dec 2024

View live Supernus Pharmaceuticals share price in Dollar and Rupees. Guide to invest in Supernus Pharmaceuticals from India. Also see the sentimental analysis on Indian investors investing in Supernus Pharmaceuticals. Get details on the Indian mutual funds that are investing in Supernus Pharmaceuticals. Get Analyst recommendations and forecasts along with all the Supernus Pharmaceuticals's financials.

Supernus Pharmaceuticals share price movements

Today's Low: $35.04
Today's High: $35.60
$35.60
1.57%
Downside
Day's Volatility :1.57%
Upside
0.0%
52 Weeks Low: $25.53
52 Weeks High: $39.37
$35.60
28.29%
Downside
52 Weeks Volatility :35.15%
Upside
9.58%

Supernus Pharmaceuticals Returns

Period	Supernus Pharmaceuticals Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	15.7%	-9.0%	0.0%
6 Months	32.49%	-4.6%	0.0%
1 Year	19.95%	3.0%	0.0%
3 Years	14.76%	0.0%	-21.1%

Supernus Pharmaceuticals Key Statistics

in dollars & INR

Previous Close	$35.59
Open	$35.44
Today's High	$35.6
Today's Low	$35.04
Market Capitalization	$2.0B
Today's Volume	$124.8K
52 Week High	$39.37
52 Week Low	$25.53
Revenue TTM	$652.0M
EBITDA	$144.0M
Earnings Per Share (EPS)	$1.07
PE Ratio	33.27
Profit Margin	9.16%
Quarterly Earnings Growth YOY	-0.99%
Return On Equity TTM	6.22%

How to invest in Supernus Pharmaceuticals from India?

It is very easy for Indian residents to invest directly in Supernus Pharmaceuticals from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Supernus Pharmaceuticals stock in both Indian Rupees (INR) and US Dollars (USD). Search for Supernus Pharmaceuticals or SUPN on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Supernus Pharmaceuticals or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Supernus Pharmaceuticals shares which would translate to 0.024 fractional shares of Supernus Pharmaceuticals as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Supernus Pharmaceuticals, in just a few clicks!

Returns in Supernus Pharmaceuticals for Indian investors in Rupees

Investment Value

₹1,00,000

Supernus Pharmaceuticals investment value today

Current value as on today

₹1,22,185

Returns

₹22,185

(+22.18%)

Returns from Supernus Pharmaceuticals Stock

₹19,946 (+19.95%)

Dollar Returns

₹2,239 (+2.24%)

Indian investors sentiment towards Supernus Pharmaceuticals

133%

Period: Sep 26, 2024 to Dec 25, 2024. Change in 30 Days versus previous period

Search volume for Supernus Pharmaceuticals on INDmoney from India has grown in the last 30 days as on Dec 26, 2024. 133% more investors are searching Supernus Pharmaceuticals in the last 30 days versus the previous period.

Global Institutional Holdings in Supernus Pharmaceuticals

BlackRock Inc
18.82%
Vanguard Group Inc
11.10%
Armistice Capital, LLC
9.23%
Dimensional Fund Advisors, Inc.
5.22%
Macquarie Group Ltd
4.77%
State Street Corp
3.91%

Analyst Recommendation on Supernus Pharmaceuticals

Buy

80%Buy

20%Hold

0%Sell

Based on 10 Wall street analysts offering stock ratings for Supernus Pharmaceuticals(by analysts ranked 0 to 5 stars)

Based on 10 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Supernus Pharmaceuticals

What analysts predicted

Upside of 10.25%

Current:

$35.60

Target:

$39.25

Insights on Supernus Pharmaceuticals

Price Movement
In the last 3 months, SUPN stock has moved up by 15.7%
Increasing Revenue
Revenue is up for the last 3 quarters, 143.64M → 175.68M (in $), with an average increase of 9.4% per quarter
Increasing Net Profit
Netprofit is up for the last 3 quarters, 124.0K → 38.49M (in $), with an average increase of 73.8% per quarter

Supernus Pharmaceuticals Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$408.9M	↑ 35.29%
Net Income	$111.0M	↑ 93.76%
Net Profit Margin	27.14%	↑ 8.19%

	FY19	Y/Y Change
Revenue	$392.8M	↓ 3.95%
Net Income	$113.1M	↑ 1.86%
Net Profit Margin	28.79%	↑ 1.65%

	FY20	Y/Y Change
Revenue	$520.4M	↑ 32.5%
Net Income	$127.0M	↑ 12.29%
Net Profit Margin	24.39%	↓ 4.4%

	FY21	Y/Y Change
Revenue	$579.8M	↑ 11.41%
Net Income	$53.4M	↓ 57.92%
Net Profit Margin	9.21%	↓ 15.18%

	FY22	Y/Y Change
Revenue	$667.2M	↑ 15.09%
Net Income	$60.7M	↑ 13.64%
Net Profit Margin	9.1%	↓ 0.11%

	FY23	Y/Y Change
Revenue	$607.5M	↓ 8.95%
Net Income	$1.3M	↓ 97.83%
Net Profit Margin	0.22%	↓ 8.88%

	Q2 FY23	Q/Q Change
Revenue	$135.6M	↓ 11.84%
Net Income	$-831.0K	↓ 104.9%
Net Profit Margin	-0.61%	↓ 11.63%

	Q3 FY23	Q/Q Change
Revenue	$153.9M	↑ 13.51%
Net Income	$-16.0M	↑ 1822.5%
Net Profit Margin	-10.38%	↓ 9.77%

	Q4 FY23	Q/Q Change
Revenue	$164.3M	↑ 6.78%
Net Income	$1.2M	↓ 107.35%
Net Profit Margin	0.72%	↑ 11.1%

	Q1 FY24	Q/Q Change
Revenue	$143.6M	↓ 12.58%
Net Income	$124.0K	↓ 89.45%
Net Profit Margin	0.09%	↓ 0.63%

	Q2 FY24	Q/Q Change
Revenue	$168.3M	↑ 17.18%
Net Income	$19.9M	↑ 15961.29%
Net Profit Margin	11.83%	↑ 11.74%

	Q3 FY24	Q/Q Change
Revenue	$175.7M	↑ 4.37%
Net Income	$38.5M	↑ 93.3%
Net Profit Margin	21.91%	↑ 10.08%

	FY18	Y/Y Change
Profit	$393.5M	↑ 37.11%

	FY19	Y/Y Change
Profit	$376.1M	↓ 4.43%

	FY20	Y/Y Change
Profit	$467.9M	↑ 24.42%

	FY21	Y/Y Change
Profit	$504.7M	↑ 7.86%

	FY22	Y/Y Change
Profit	$580.0M	↑ 14.92%

	FY23	Y/Y Change
Profit	$523.7M	↓ 9.7%

	Q2 FY23	Q/Q Change
Profit	$114.5M	↓ 12.15%

	Q3 FY23	Q/Q Change
Profit	$134.3M	↑ 17.3%

	Q4 FY23	Q/Q Change
Profit	$123.0M	↓ 8.39%

	Q1 FY24	Q/Q Change
Profit	$106.6M	↓ 13.35%

	Q2 FY24	Q/Q Change
Profit	$129.7M	↑ 21.69%

	Q3 FY24	Q/Q Change
Profit	$138.0M	↑ 6.41%

	FY18	Y/Y Change
Operating Cash Flow	$129.0M	↑ 12.51%
Investing Cash Flow	$-413.5M	↑ 378.48%
Financing Cash Flow	$376.4M	↑ 6526.26%

	FY19	Y/Y Change
Operating Cash Flow	$143.1M	↑ 10.96%
Investing Cash Flow	$-157.9M	↓ 61.81%
Financing Cash Flow	$3.9M	↓ 98.96%

	FY20	Y/Y Change
Operating Cash Flow	$138.4M	↓ 3.3%
Investing Cash Flow	$-34.7M	↓ 78.03%
Financing Cash Flow	$3.6M	↓ 9.39%

	FY21	Y/Y Change
Operating Cash Flow	$127.1M	↓ 8.14%
Investing Cash Flow	$-81.9M	↑ 136.07%
Financing Cash Flow	$-130.4M	↓ 3764.51%

	FY22	Y/Y Change
Operating Cash Flow	$116.8M	↓ 8.1%
Investing Cash Flow	$-216.7M	↑ 164.5%
Financing Cash Flow	$-10.5M	↓ 91.97%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-18.9M	↓ 138.42%
Investing Cash Flow	$60.3M	↓ 74.85%
Financing Cash Flow	$-478.9M	↓ 697.35%

Supernus Pharmaceuticals Technicals Summary

Sell

Neutral

Buy

Supernus Pharmaceuticals is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Supernus Pharmaceuticals Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Supernus Pharmaceuticals Inc	-1.49%	32.49%	19.95%	14.76%	52.5%
Neurocrine Biosciences Inc.	6.74%	1.65%	2.84%	61.59%	27.41%
Haleon Plc Spon Ads	1.56%	15.54%	17.63%	31.44%	31.44%
Zoetis Inc.	-6.26%	-6.66%	-16.35%	-33.19%	24.57%
Viatris Inc.	-5.2%	18.32%	15.13%	-9.29%	-24.11%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Supernus Pharmaceuticals Inc	33.27	33.27	1.47	2.86	0.06	0.03	NA	18.24
Neurocrine Biosciences Inc.	36.41	36.41	0.32	6.37	0.16	0.12	NA	26.87
Haleon Plc Spon Ads	29.52	29.52	1.76	0.34	0.07	0.04	0.02	1.82
Zoetis Inc.	30.96	30.96	2.56	5.88	0.47	0.15	0.01	11.59
Viatris Inc.	224.4	NA	0.07	2.69	-0.04	0.02	0.04	16.58

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Supernus Pharmaceuticals Inc	Buy	$2.0B	52.5%	33.27	9.16%
Neurocrine Biosciences Inc.	Buy	$13.8B	27.41%	36.41	17.21%
Haleon Plc Spon Ads	Buy	$44.0B	31.44%	29.52	10.75%
Zoetis Inc.	Buy	$74.3B	24.57%	30.96	26.55%
Viatris Inc.	Hold	$14.8B	-24.11%	224.4	-5.87%

About Supernus Pharmaceuticals

pioneering new medicines in neurology and psychiatry with more than 20 years of experience, we are a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (cns) disorders. in 2013 we launched oxtellar xr® and trokendi xr®, two novel neurology products for the treatment of epilepsy. we are also developing several product candidates in psychiatry to address unmet medical needs and opportunities in attention-deficit hyperactivity disorder (adhd) and its coexisting disorders, and depression. we are developing differentiated products by leveraging our proprietary and in-licensed technologies. we use such technologies to discover and develop novel uses for known drug compounds and to enhance their therapeutic benefits. our focus on known drug compounds with established mechanisms of action reduces the risks, costs, and time typically associated with pharmaceutical product development.

Organization	Supernus Pharmaceuticals
Employees	652
CEO	Mr. Jack A. Khattar M.B.A.
Industry	Health Technology

Management People of Supernus Pharmaceuticals

Name	Title
Mr. Jack A. Khattar M.B.A.	Founder, President, CEO, Secretary & Director
Mr. Timothy C. Dec	Senior VP & CFO
Dr. Padmanabh P. Bhatt Ph.D.	Chief Scientific Officer & Senior VP of Intellectual Property
Mr. Frank Mottola	Senior Vice President of Quality, GMP Operations, Information Technology and Regulatory Affairs
Dr. Jonathan Rubin M.B.A., M.D.	Senior VP of Research & Development and Chief Medical Officer
Mr. Kevin T. Anderson Esq.	Compliance Officer
Dr. Todd Horich M.B.A., Ph.D.	Senior Vice President of Marketing, Commercial Operations & Market Access
Mr. Taylor Raiford	Senior Vice President of Sales
Dr. Bryan A. Roecklein Ph.D.	Senior Vice President of Corporate Development
Mr. Jeff Bozick	Senior Vice President of Supply Chain

Important FAQs about investing in Supernus Pharmaceuticals from India :

What is Supernus Pharmaceuticals share price today?

Supernus Pharmaceuticals share price today stands at $35.60, Open: $35.44 ; Previous Close: $35.59 ; High: $35.60 ; Low: $35.04 ; 52 Week High: $39.37 ; 52 Week Low: $25.53. The stock opens at $35.44, after a previous close of $35.59. The stock reached a daily high of $35.60 and a low of $35.04, with a 52-week high of $39.37 and a 52-week low of $25.53.

Can Indians buy Supernus Pharmaceuticals shares?

Yes, Indians can invest in the Supernus Pharmaceuticals (SUPN) from India.

With INDmoney, you can buy Supernus Pharmaceuticals at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Supernus Pharmaceuticals at zero transaction cost.

How can I buy Supernus Pharmaceuticals shares from India?

It is very easy to buy Supernus Pharmaceuticals from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Supernus Pharmaceuticals be purchased?

Yes, you can buy fractional shares of Supernus Pharmaceuticals with INDmoney app.

What are the documents required to start investing in Supernus Pharmaceuticals stocks?

To start investing in Supernus Pharmaceuticals, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.